Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Jieqiong Wang; Kewen Hu; Jiawei Guo; Feixiong Cheng; Jing Lv; Wenhao Jiang; Weiqiang Lu; Jinsong Liu; Xiufeng Pang; Mingyao Liu

doi:10.1038/ncomms11363

Nature Communications (May 2016)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Jieqiong Wang,
Kewen Hu,
Jiawei Guo,
Feixiong Cheng,
Jing Lv,
Wenhao Jiang,
Weiqiang Lu,
Jinsong Liu,
Xiufeng Pang,
Mingyao Liu

Affiliations

Jieqiong Wang: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Kewen Hu: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Jiawei Guo: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Feixiong Cheng: State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University
Jing Lv: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Wenhao Jiang: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Weiqiang Lu: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Jinsong Liu: Department of Pathology, The University of Texas MD Anderson Cancer Center
Xiufeng Pang: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University
Mingyao Liu: Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University

DOI: https://doi.org/10.1038/ncomms11363
Journal volume & issue: Vol. 7, no. 1
pp. 1 – 13

Abstract

Read online

KRas is frequently mutated in multiple cancer types; identifying drugs to treat such cancers is a good therapeutic strategy. Here, the authors perform a synthetic lethal screen in mice and show that inhibiting Plk1 and ROCK results in the inhibition of tumour growth by increasing expression of the tumour suppressor p21.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal